Modulation of the differentiation status of cultured prostatic smooth muscle cells by an α1-adrenergic receptor antagonist

Prostate

Volumn 39, Issue 4, 1999, Pages 226-233

  Boesch, Simone T ^a   Corvin, Stefan ^a   Zhang, Ju ^a,c   Rogatsch, Hermann ^b   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c NANKAI UNIVERSITY   (China)

Author keywords

1 adrenergic receptor subtypes; Differentiation; Doxazosin; Phenylephrine; Smooth muscle cells; Smooth muscle myosin heavy chain subtypes

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; DOXAZOSIN; MYOSIN HEAVY CHAIN; PHENYLEPHRINE;

ARTICLE; DRUG EFFECT; GROWTH REGULATION; HUMAN; HUMAN CELL; MALE; MUSCLE DEVELOPMENT; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR DENSITY; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE FIBER;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; CELL DIVISION; CELLS, CULTURED; DNA PRIMERS; DOXAZOSIN; GENE EXPRESSION REGULATION; HUMANS; MALE; MUSCLE, SMOOTH; MYOSIN SUBFRAGMENTS; MYOSIN-LIGHT-CHAIN KINASE; PEPTIDE FRAGMENTS; PHENYLEPHRINE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0033152621     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990601)39:4<226::AID-PROS2>3.0.CO;2-8     Document Type: Article

References (26)

1. Cunha GR. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 1994;74:1030-1044.
2. Cunha GR. Mesenchymal-epithelial interactions during androgen-induced development of the prostate. In: Lash JW, Saxon L, editors. Developmental mechanisms: normal and abnormal. New York: Alan R. Liss; 1985. p 15-24.
3. Bartsch G, Brüngger A, Schweikert U, Hintner H, Höpfl R, Rohr H. Benign prostatic hyperplasia: morphometric studies in relation to the pathogenesis. New Dev Biosci 1989;5:34-53.
4. Shapiro E, Becich MJ, Hartanto V, Lepor H. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 1992;147:1293-1297.
5. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997;30:202-215.
6. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 1986;136:1-4.
7. Andersen JT. Alpha 1-blockers vs. 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review. Drugs Aging 1995;6:388-396.
8. Chapple CR. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996;29:129-144.
9. Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, Hittmair A, Culig Z, Bartsch G, Klocker H. Human prostatic smooth muscle cells in culture: estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997; 30:117-129.
10. Corvin S, Bosch ST, Eder I, Thurnher M, Bartsch G, Klocker H. Videoimaging of prostatic stromal-cell contraction: an in vitro model for studying drug effects. Prostate 1998;37:209-214.
11. Aikawa M, Sivam PN, Kuro M, Kimura K, Nakahara K, Takewaki S, Ueda M, Yamaguchi H, Yazaki Y, Periasamy M. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res 1993;73:1000-1012.
12. Frid MG, Shekhonin BV, Koteliansky VE, Glukhova MA. Phenotypic changes of human smooth muscle cells during development: late expression of heavy caldesmon and calponin. Dev Biol 1992;153:185-193.
13. Frid MG, Printesva OY, Chiavegato A, Faggin E, Scatena M, Koteliansky VE, Pauletto P, Glukhova MA, Sartore S. Myosin heavy-chain isoform composition and distribution in developing and adult human aortic smooth muscle. J Vasc Res 1993;30: 279-292.
14. Aikawa M, Kim HS, Kuro M, Manabe I, Watanabe M, Yamaguchi H, Yazaki Y, Nagai R. Phenotypic modulation of smooth muscle cells during progression of human atherosclerosis as determined by altered expression of myosin heavy chain isoforms. Ann NY Acad Sci 1995;748:578-585.
15. Samuel M, Kim Y, Horiuchi KY, Levin RM, Chacko S. Smooth muscle myosin isoform distribution and myosin ATPase in hypertrophied urinary bladder. Biochem Int 1992;26:645-652.
16. Cher ML, Abernathy BB, McConnell JD, Zimmern PE, Lin VK. Smooth-muscle myosin heavy-chain isoform expression in bladder-outlet obstruction. World J Urol 1996;14:295-300.
17. Eder IE, Stenzl A, Hobisch A, Cronauer MV, Bartsch G, Klocker H. Transforming growth factors-beta 1 and beta 2 in serum and urine from patients with bladder carcinoma. J Urol 1996;156: 953-957.
18. Cronauer MV, Hittmair A, Eder IE, Hobisch A, Culig Z, Ramoner R, Zhang J, Bartsch G, Reissigl A, Radmayr C, Thurnher M, Klocker H. Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate 1997;31:223-233.
19. Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M. Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun 1994;201: 1296-1304.
20. Dausse JP, Leriche A, Yablonsky F. Patterns of messenger RNA expression for alpha 1-adrenoceptor subtypes in human corpus cavernosum. J Urol 1998;160:597-600.
21. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alphal adrenergic receptor subtypes in human prostate. J Urol 1993;150:546-551.
22. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D. Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci 1994;54:1595-1605.
23. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995;22:375-386.
24. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-1815.
25. Pool JL. Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract 1996;50:154-163.
26. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J 1991;121:251-260.